Filing Details

Accession Number:
0001209191-22-060227
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-07 17:58:18
Reporting Period:
2022-12-05
Accepted Time:
2022-12-07 17:58:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1347178 Vanda Pharmaceuticals Inc. VNDA Pharmaceutical Preparations (2834) 030491827
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1355537 Hristos Mihael Polymeropoulos 2200 Pennsylvania Avenue
Suite 300E
Washington DC 20037
President And Ceo Yes Yes No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-12-05 74,635 $3.12 1,427,401 No 4 M Direct
Common Stock Disposition 2022-12-05 47,650 $10.62 1,379,751 No 4 S Direct
Common Stock Acquisiton 2022-12-06 75,365 $3.12 1,455,116 No 4 M Direct
Common Stock Disposition 2022-12-06 48,250 $10.61 1,406,866 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-12-05 74,635 $0.00 74,635 $3.12
Common Stock Stock Option (Right to Buy) Disposition 2022-12-06 75,365 $0.00 75,635 $3.12
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
75,365 2022-12-06 No 4 M Direct
0 2022-12-06 No 4 M Direct
Footnotes
  1. Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 6, 2022 as reflected in this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.43 to $10.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.39 to $10.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
  4. This option fully vested and exercisable.